LivaNova PLC

LivaNova PLC is a medical technology company that designs, manufactures, and markets products for cardiac surgery and neuromodulation therapies. Its portfolio includes heart‑lung machines, perfusion systems, vascular grafts, and devices that deliver vagus nerve stimulation for the treatment of epilepsy and depression. The company serves hospitals, surgical centers, and healthcare providers in markets across the world, supplying equipment that supports life‑saving procedures and chronic disease management. LivaNova’s offerings are intended to improve patient outcomes by enabling precise control of blood flow during surgery and modulating neural activity for therapeutic benefit. The firm’s activities are subject to stringent regulatory oversight from agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, reflecting the safety‑critical nature of its devices.

The organization’s headquarters is located in the United Kingdom, as indicated in its official disclosures. A cybersecurity incident reported on 1 November 2023 disrupted portions of LivaNova’s information technology systems, prompting an investigation with external experts and coordination with law enforcement. The company responded by taking certain systems offline, which initially caused disruptions to business operations but later allowed its manufacturing sites to return to substantially normal levels. This episode confirms that LivaNova maintains manufacturing facilities in multiple locations, as the restoration of those sites was noted as a key milestone in the incident response. While the full financial and operational impact of the event remained under assessment at the time of the disclosure, the incident highlighted the global reach of the company’s production and IT infrastructure.

LivaNova distinguishes itself through its dual focus on cardiac surgery perfusion technology and neuromodulation, two specialized fields that require deep expertise in both engineering and biomedical science. Its longstanding involvement in perfusion technology positions it as a provider of critical equipment used in open‑heart surgery and other complex cardiovascular procedures. In the neuromodulation arena, the company’s vagus nerve stimulation platform represents a differentiated therapeutic option for patients with drug‑resistant epilepsy and treatment‑resistant depression. These competencies are supported by a regulatory framework that demands rigorous pre‑market testing, post‑market surveillance, and adherence to quality‑system standards. As a publicly traded entity listed under the ticker LIVN on major exchanges, LivaNova operates as an independent PLC with ownership dispersed among institutional and retail shareholders, without a disclosed parent company in the provided sources.